Piramal Pharma Achieves Significant Improvement in Sustainability Assessment Score for 2025
Piramal Pharma Limited (PPL), a notable entity in the global pharmaceutical landscape, has made headlines with its impressive sustainability score of 63 in the 2025 S&P Global Corporate Sustainability Assessment (CSA). This achievement marks a remarkable 15% increase from last year's score of 55, asserting PPL's strong commitment to sustainability and responsible operations.
The S&P Global CSA is one of the most comprehensive annual assessments that benchmark the sustainability efforts of thousands of companies across various sectors. It evaluates organizations on criteria including environmental, social, and governance (ESG) performance, governance maturity, and capacity for long-term value creation. By ranking in the 91st percentile within the pharmaceutical industry, PPL not only stands out among competitors but also fortifies the confidence of clients and global investors.
PPL's dedication to sustainability is further underscored by its initiatives aimed at reducing its environmental footprint. A prime example includes the recent installation of a 240 kWp rooftop solar system at their Digwal facility. Launched in April 2024, this solar energy initiative is anticipated to yield around 607 GJ of renewable power in FY2025, aiding the company in reducing its carbon emissions by approximately 123 tCO₂e. Such steps highlight PPL's ongoing efforts to integrate clean energy into its operational framework.
The impressive score improvement reflects PPL's four-pillar sustainability strategy, which incorporates ESG principles into every facet of operations. The pillars include:
This multifaceted approach positions PPL as a leader in sustainable practices, showcasing the importance of environmental responsibility in today's corporate landscape. According to Peter DeYoung, CEO of Piramal Global Pharma, "Our progress on the SP Global CSA underscores our unwavering dedication to responsible operations and sustainable growth. As we continue to expand, we remain committed to excellence in every aspect of our work, ensuring our initiatives contribute to a healthier future for all."
Looking forward, PPL aims to build on this momentum. The insights gained from the S&P Global CSA will be vital in enhancing their sustainability strategies and continuing to drive positive change within their operations and for their partners. In addition to the aforementioned solar installation, PPL is involved in various innovations aimed at improving their product offerings while adhering to sustainable practices.
Piramal Pharma Limited operates a comprehensive range of services through its global development and manufacturing facilities, extending its influence across over 100 countries. The company includes several business lines such as Piramal Pharma Solutions, a prominent contract development and manufacturing organization, and Piramal Critical Care, which focuses on complex hospital generics. With recent collaborations, such as an associate venture with Abbvie Therapeutics India, PPL has solidified its presence in the ophthalmology market, emerging as a leader in the pharmaceutical domain.
For more information and updates on ongoing sustainability efforts, you can visit Piramal Pharma’s official website or follow their LinkedIn page. The journey towards sustainability is an ongoing one, and PPL is determined to lead by example, fostering a better environment through responsible business practices.
The S&P Global CSA is one of the most comprehensive annual assessments that benchmark the sustainability efforts of thousands of companies across various sectors. It evaluates organizations on criteria including environmental, social, and governance (ESG) performance, governance maturity, and capacity for long-term value creation. By ranking in the 91st percentile within the pharmaceutical industry, PPL not only stands out among competitors but also fortifies the confidence of clients and global investors.
PPL's dedication to sustainability is further underscored by its initiatives aimed at reducing its environmental footprint. A prime example includes the recent installation of a 240 kWp rooftop solar system at their Digwal facility. Launched in April 2024, this solar energy initiative is anticipated to yield around 607 GJ of renewable power in FY2025, aiding the company in reducing its carbon emissions by approximately 123 tCO₂e. Such steps highlight PPL's ongoing efforts to integrate clean energy into its operational framework.
The impressive score improvement reflects PPL's four-pillar sustainability strategy, which incorporates ESG principles into every facet of operations. The pillars include:
- - Business Resilience: Building a robust framework to support sustainable business practices.
- - Quality Excellence: Committing to the highest standards in product and service delivery.
- - Responsible Operations: Ensuring that all operations are compliant and ethical.
- - Stakeholder Centricity: Engaging with stakeholders to create mutually beneficial relationships.
This multifaceted approach positions PPL as a leader in sustainable practices, showcasing the importance of environmental responsibility in today's corporate landscape. According to Peter DeYoung, CEO of Piramal Global Pharma, "Our progress on the SP Global CSA underscores our unwavering dedication to responsible operations and sustainable growth. As we continue to expand, we remain committed to excellence in every aspect of our work, ensuring our initiatives contribute to a healthier future for all."
Looking forward, PPL aims to build on this momentum. The insights gained from the S&P Global CSA will be vital in enhancing their sustainability strategies and continuing to drive positive change within their operations and for their partners. In addition to the aforementioned solar installation, PPL is involved in various innovations aimed at improving their product offerings while adhering to sustainable practices.
Piramal Pharma Limited operates a comprehensive range of services through its global development and manufacturing facilities, extending its influence across over 100 countries. The company includes several business lines such as Piramal Pharma Solutions, a prominent contract development and manufacturing organization, and Piramal Critical Care, which focuses on complex hospital generics. With recent collaborations, such as an associate venture with Abbvie Therapeutics India, PPL has solidified its presence in the ophthalmology market, emerging as a leader in the pharmaceutical domain.
For more information and updates on ongoing sustainability efforts, you can visit Piramal Pharma’s official website or follow their LinkedIn page. The journey towards sustainability is an ongoing one, and PPL is determined to lead by example, fostering a better environment through responsible business practices.
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.